1H-benzo[1,2,6]thiadiazine 2,2-dioxide | 33853-38-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 英文名称: 1H-benzo[1,2,6]thiadiazine 2,2-dioxide
• 英文别名: 1H-2.1.3-Benzothiadiazin-2.2-dioxide；1H-2λ6,1,3-benzothiadiazine 2,2-dioxide
• CAS: 33853-38-2
• 化学式: C₇H₆N₂O₂S
• 分子量: 182.203
• InChiKey: XCXVPQAXJPZYNW-UHFFFAOYSA-N

物化性质

• 沸点：
  380.1±25.0 °C(Predicted)
• 密度：
  1.54±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  溴甲苯 、 1H-benzo[1,2,6]thiadiazine 2,2-dioxide 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 1-benzyl-1H-benzo[1,2,6]thiadiazine 2,2-dioxide
  参考文献：
  名称：

  1H-2.1.3-Benzothiadiazin-2.2-dioxide Cyclische und bicyclische Sulfamide, 2. Mitt.

  摘要：

  DOI：

  10.1007/bf00909932
• 作为产物：
  描述：

  3,4-dihydro-1H-benzo[1,2,6]thiadiazine 2,2-dioxide 生成 1H-benzo[1,2,6]thiadiazine 2,2-dioxide
  参考文献：
  名称：

  �ber die Umsetzung von 6-Chlor-4-phenyl-3,4-dihydro-1H-2,1,3-benzothiadiazin-2,2-dioxid mit 1,4-Dijodbutan

  摘要：

  DOI：

  10.1007/bf00917212

文献信息

• METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER
  申请人：TACHDJIAN Catherine

  公开号：US20120041078A1

  公开（公告）日：2012-02-16

  The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.

  本发明包括在甜味增强剂暴露于光源时稳定一个或多个甜味增强剂的方法，以及包含一个或多个甜味增强剂和一个或多个光稳定剂的液体组合物。
• [EN] HEAT SHOCK PROTEIN MODULATORS AND ANTI-HUNTINGTON DISEASE THERAPEUTIC AGENTS<br/>[FR] MODULATEURS DE PROTÉINE DE CHOC THERMIQUE ET AGENTS THÉRAPEUTIQUES ANTI-MALADIE DE HUNTINGTON
  申请人：UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION

  公开号：WO2021163513A1

  公开（公告）日：2021-08-19

  Disclosed are thiadiazine compounds, derivatives and compositions thereof. The compounds, derivatives, and compositions can be used for treating or preventing a heat-shock protein responsive disorder or suppressing protein aggregation in a subject. The compounds and compositions can also be used for treating cancer, neurodegenerative disorders, and other heat-shock protein responsive disorders.

  本文披露了噻二唑烷化合物及其衍生物和组合物。这些化合物、衍生物和组合物可用于治疗或预防热休克蛋白应答性疾病或抑制受试者中的蛋白聚集。这些化合物和组合物还可用于治疗癌症、神经退行性疾病和其他热休克蛋白应答性疾病。
• MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH
  申请人：Tachdjian Catherine

  公开号：US20080306053A1

  公开（公告）日：2008-12-11

  The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.

  本发明提供了用于识别化学感受受体及其配体的修饰因子的筛选方法，例如，通过确定测试实体是否适合与化学感受受体的捕蝇草结构域内的一个或多个相互作用位点发生相互作用，以及能够调节化学感受受体及其配体的修饰因子。
• [EN] 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM<br/>[FR] DERIVES DE 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE ET DERIVES DE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXYDE ET DE 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE RESPECTIFS, UTILISES COMME MODULATEURS DU RECEPTEUR DE LA 5-HYDROXYTRYPTAMINE (5-HT) POUR LE TRAITEMENT D'AFFECTIONS DU SYSTEME NERVEUX CENTRAL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005067933A1

  公开（公告）日：2005-07-28

  The invention relates to substituted quinazolinone compunds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C or S; m is 1 when Y is C and m is 2 when Y is S; n is 1 or 2; p is from 0 to 3; q is from 1 to 3; Z is -(CRaRb)r- or -SO2-, wherein r is from 0 to 2 and each of Ra and Rb is independently hydrogen or alkyl; X is CH or N; R2 is optionally substituted aryl or optionally substituted heteroaryl; preferably R2 is aryl, and more preferably phenyl optionally substituted by one or more trifluoromethyl, halo, cyano, C1-C6 alkyl or C1-C6 alkoxy; A is -NR3- or -O- wherein R3 is: hydrogen; alkyl, acyl, amidoalkyl, hydroxyalkyl or alkoxyalkyl; the other substituents are defined in the claims. The compounds are modulators of the 5-hydroxytryptamine receptor and are useful for the treatment of diseases of the central nervous system such as psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit disorder, Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease, food uptake disorders, and Huntington’s disease.

  该发明涉及式(I)的取代喹唑啉酮化合物或其药学上可接受的盐，其中Y为C或S；当Y为C时，m为1，当Y为S时，m为2；n为1或2；p为0到3；q为1到3；Z为-(CRaRb)r-或-SO2-，其中r为0到2，Ra和Rb各自独立地为氢或烷基；X为CH或N；R2为可选择地取代的芳基或可选择地取代的杂环烷基；优选R2为芳基，更优选为苯基，可选地取代为一个或多个三氟甲基，卤素，氰基，C1-C6烷基或C1-C6烷氧基；A为-NR3-或-O-，其中R3为：氢；烷基，酰基，酰胺烷基，羟基烷基或烷氧基烷基；其他取代基在权利要求中定义。这些化合物是5-羟色胺受体的调节剂，可用于治疗中枢神经系统疾病，如精神病、精神分裂症、躁郁症、神经系统疾病、记忆障碍、注意力缺陷障碍、帕金森病、肌萎缩侧索硬化症、阿尔茨海默病、摄食障碍和亨廷顿病。
• NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT
  申请人：Kusuda Shinya

  公开号：US20090131403A1

  公开（公告）日：2009-05-21

  The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so on. Wherein all symbols in formula are as defined in the specification

  公式（I）所代表的化合物，其盐，其N-氧化物，其溶剂合物或其前药，具有特异性地结合CCR5，因此对于预防和/或治疗CCR5相关疾病非常有用，例如各种炎症性疾病（哮喘，肾炎，肾病，肝炎，关节炎，类风湿性关节炎，鼻炎，结膜炎，溃疡性结肠炎等），免疫性疾病（自身免疫性疾病，器官移植排斥反应，免疫抑制，银屑病，多发性硬化症等），传染性疾病（感染人类免疫缺陷病毒，获得性免疫缺陷综合症等），过敏性疾病（特应性皮炎，荨麻疹，过敏性支气管肺曲霉病，过敏性嗜酸性胃肠炎等），缺血再灌注损伤，急性呼吸窘迫综合症，细菌感染引起的休克，糖尿病，癌症转移等。其中，公式中的所有符号均如规范中所定义。